News
Eisai to Present Latest Data at 10th Clinical Trials on Alzheimer’s Diesase
Eisai Co., Ltd. announced that the latest data on its oral dual orexin receptor antagonist lemborexant and its oral beta secretase cleaving enzyme (BACE)...
Research Insight
InVitria Announces New Media Formulation Service
InVitria, a division of Ventria Bioscience, has announced the launch of a new media formulation service at the international BIO-Europe conference in Berlin, Germany. ...
News
SOTIO Completes Enrolment of Phase III VIABLE Study in Late Stage Prostate Cancer
SOTIO, a biotechnology company owned by the PPF Group, announced the enrolment of the last patient into the VIABLE study, a global Phase III...
Press Releases
CluePoints Builds on Late Phase work in Japan and Launches Risk-Based Monitoring Roadshow in Tokyo
CluePoints, a leading provider of Risk-Based Monitoring (RBM) and Data Quality Oversight solutions for clinical trials, has further expanded its Late Phase work in...
Articles
Auditory Therapy, Ototoxicity and GLP Compliance Will the promising market for ear disorder treatments follow ophthalmology’s dramatic growth curve?
The numbers are daunting – 15% of the global population suffers from hearing loss, including a significant number of children, teenagers, and the elderly....
Industry Reports
Celonic Acquires Glycotope’s Bio-manufacturing Facility
Celonic AG, a leading global biologics development and manufacturing services provider, and Glycotope, a clinical stage immune-oncology company, today announced the successful completion of...
Articles
Direct-to-Patient Solutions Assuring Patient Participation and Retention in Clinical Trials
The average cost of bringing a new drug to market is $2.6 billion, according to a 2014 report published by Tufts Center for the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read